ResMed reported a strong second quarter of fiscal year 2025 (QQ2 2025), with revenue of $1.282 billion, up 10% year over year and 4.7% quarter over quarter. Non-GAAP gross margin expanded 230 basis points to 59.2%, supported by manufacturing/logistics efficiencies and component cost improvements, while operating profit rose 19% and net income advanced 29% YoY. The company also highlighted robust growth across devices, masks/accessories and the residential care software portfolio (notably MEDIFOX/DAN). Management reaffirmed a 59–60% gross margin range for the second half of FY2025 and guided SG&A and R&D as percentages of revenue to roughly 18–20% and 6–7%, respectively. The quarter featured meaningful product and strategic momentum (AirSense 11 launches including India, Brightree ReSupply/Snap expansion, and fabric-based AirTouch N30i) paired with top-line drivers from global demand for sleep and breathing health, and a nascent but material-to-long-term tailwind from GLP-1 therapies and consumer wearables detection of sleep apnea. The results reinforce ResMed’s three-pillar strategy (grow/differentiate core business, expand adjacencies like COPD/COMISA, and leverage digital health leadership) and position the company well for durable growth, subject to FX volatility and regulatory/pharma‑adjacent dynamics.